Lipoprotein management in patients with cardiometabolic risk: consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation.

Description

The latest issue of Diabetes Care and the Journal of the American College of Cardiology presents a consensus conference report from the American Diabetes Association and the American College of Cardiology Foundation on the topic of lipoprotein management in patients with cardiometabolic risk (CMR). The extent to which lipoproteins contribute to the development of cardiovascular disease (CVD) and the issues surrounding the central role of LDL (quality and quantity) in the pathophysiology of CMR are discussed. Several risk factors and emerging CMR markers associated with lipoprotein-lipid metabolism are mentioned and discussed, as are their roles in the development of CMR. There is also a very informative section entitled “What are the principles and objectives of treatment of lipoprotein abnormalities” that could help physicians and/or health professionals set achievable goals regarding lipoprotein levels for patients with CMR. The authors also highlighted several areas of research that warrant attention, such as the issue of residual risk (beyond LDL) in patients on statin therapy.